Integrated single-cell transcriptomic analysis of brain and lymph node metastases in non-small cell lung cancer

Table 1 scRNA-seq cohorts

Dataset	Sample	Tissue origin	Histology	Sex	Age (years)
GSE131907	BRONCHO_11	mLN	ADC	Female	81
GSE131907	EBUS_10	mLN	ADC	Male	68
GSE131907	EBUS_12	mLN	ADC	Female	60
GSE131907	EBUS_13	mLN	ADC	Male	53
GSE131907	EBUS_15	mLN	ADC	Male	64
GSE131907	EBUS_19	mLN	ADC	Female	68
GSE131907	EBUS_51	mLN	ADC	Male	43
GSE131907	LN_01	nLN	ADC	Male	61
GSE131907	LN_02	nLN	ADC	Female	66
GSE131907	LN_03	nLN	ADC	Male	67
GSE131907	LN_04	nLN	ADC	Male	67
GSE131907	LN_05	nLN	ADC	Female	56
GSE131907	LN_06	nLN	ADC	Female	63
GSE131907	LN_07	nLN	ADC	Male	68
GSE131907	LN_08	nLN	ADC	Female	77
GSE131907	LN_11	nLN	ADC	Male	74
GSE131907	LN_12	nLN	ADC	Male	62
GSE131907	LUNG_T06	tLung	ADC	Male	54
GSE131907	LUNG_T08	tLung	ADC	Female	60
GSE131907	LUNG_T09	tLung	ADC	Male	67
GSE131907	LUNG_T18	tLung	ADC	Male	62
GSE131907	LUNG_T19	tLung	ADC	Male	53
GSE131907	LUNG_T20	tLung	ADC	Male	55
GSE131907	LUNG_T25	tLung	ADC (Double)	Male	69
GSE131907	LUNG_T28	tLung	ADC (Double)	Male	73
GSE131907	LUNG_T30	tLung	ADC	Male	56
GSE131907	LUNG_T31	tLung	ADC	Male	65
GSE131907	LUNG_T34	tLung	ADC	Male	64
GSE131907	NS_02	mBrain	ADC	Female	46
GSE131907	NS_03	mBrain	ADC	Female	81
GSE131907	NS_04	mBrain	ADC	Male	39
GSE131907	NS_06	mBrain	ADC	Male	59
GSE131907	NS_07	mBrain	ADC	Female	64
GSE131907	NS_12	mBrain	ADC	Female	59
GSE131907	NS_13	mBrain	ADC	Female	50
GSE131907	NS_16	mBrain	ADC	Male	69
GSE131907	NS_17	mBrain	ADC	Female	56
GSE131907	NS_19	mBrain	ADC	Female	44
GSE186344	Lung-1	Frontal	Small cell neuroendocrine carcinoma	Male	76
GSE186344	Lung-2	Frontal	NSCLC	Female	57
GSE186344	Lung-3	Temporal	NSCLC	Female	62
GSE256491	TL_patient9	Right temporal lobe	NSCLC	Male	25
GSE256491	TL_patient10	Right temporal lobe	NSCLC	Male	24

NSCLC: Non-small cell lung cancer; ADC: Adenocarcinoma; nLN: Normal lymph nodes; mLN: Lymph node metastases; mBrain: Brain metastases..

Table 2 Multiplex immunohistochemistry cohorts

Group	Pathological number	Gender	Age (years)	Histology	Stage	TNM	Treatment regimens
Mets0	1037557	Male	58	ADC	I	T2aN0M0	Surgery
Mets0	1054412	Female	82	ADC	II	T2N0M0	Surgery
Mets0	1117778	Female	48	ADC	I	T2aN0M0	Surgery
Mets0	1117102	Female	61	ADC	I	T1N0M0	Surgery
Mets0	1123096	Male	58	ADC	I	T1N0M0	Surgery
Mets0	1121625	Male	51	ADC	II	T3N0M0	Chemotherapy
Mets0	1088996	Male	70	ADC	I	T1N0M0	Surgery
Mets0	1119756	Female	54	ADC	I	T1N0M0	Surgery
Mets0	1124448	Male	61	ADC	II	T2bN0M0	Surgery
Mets0	1136112	Male	68	ADC	II	T2bN0M0	Chemotherapy
Mets0	1135011	Male	60	ADC	II	T2bN0M0	Chemotherapy
Mets1	1090522	Female	48	ADC	III	T2aN2M0	Chemotherapy
Mets1	1092316	Female	53	ADC	II	T2aN1M0	Surgery
Mets1	641032	Male	50	ADC	IV	T1bN3M1b	Chemotherapy
Mets1	1099920	Female	50	ADC	II	T1bN1M0	Surgery
Mets1	1113168	Female	53	ADC	III	T2N2M0	Surgery
Mets1	1118269	Male	40	ADC	II	T2aN1M0	Surgery
Mets1	1120708	Female	58	ADC	III	T3N1M0	Surgery
Mets1	1117066	Female	79	ADC	IV	T2N1M1	Surgery
Mets1	1113386	Male	62	ADC	III	T3N2M0	Surgery
Mets1	1131710	Male	52	ADC	III	TIcN2M0	Surgery
Mets1	1128781	Male	63	ADC	III	T3N2M0	Surgery
Mets1	1145641	Male	43	ADC	II	T2N1M0	Surgery

ADC: Adenocarcinoma.